Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Michael E. Hurwitz

Oncology
Yale New Haven Health System
Yale University
20 York St, 
New Haven, CT 
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
Yale New Haven Health System
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Hurwitz is an Oncologist in New Haven, Connecticut. Dr. Hurwitz is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Adult Soft Tissue Sarcoma, and Orchiectomy.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Bridgeport Hospital
Greenwich Hospital Association -
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510
Call: 203-785-4638

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Enrollment Status: Completed
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer
A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: November 21, 2024
Intervention Type: Drug
Study Drug: Tumor infiltrating lymphocytes (TIL) LN-145
Study Phase: Phase 2
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor
A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor
Enrollment Status: Withdrawn
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pembrolizumab+Ramucirumab
Study Phase: Phase 2
View 5 Less Clinical Trials

49 Total Publications

Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.
Journal: Journal for immunotherapy of cancer
Published: August 27, 2025
View All 49 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Chung-han H. Lee
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Chung-han H. Lee
Oncology
500 Westchester Ave, 
West Harrison, NY 
 (45.7 miles away)
646-422-4545
Languages Spoken:
English
See accepted insurances

Chung-han Lee is an Oncologist in West Harrison, New York. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Renal Cell Carcinoma (RCC), and Familial Wilms Tumor 2.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rohit K. Jain
Oncology | Hematology Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rohit K. Jain
Oncology | Hematology Oncology | Hematology

New York Queens Medicine And Surgery, P.C.

5645 Main St, 
Flushing, NY 
 (60.3 miles away)
718-445-0220
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rohit Jain is an Oncologist and a Hematologist Oncology provider in Flushing, New York. Dr. Jain is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Penectomy, and Endoscopy. Dr. Jain is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shenhong G. Wu
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Shenhong G. Wu
Oncology

Stony Brook Internists University Faculty Practice Corporation

3 Edmond D Pellegrino Rd, 
Stony Brook, NY 
 (29.1 miles away)
631-638-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shenhong Wu is an Oncologist in Stony Brook, New York. Dr. Wu is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hurwitz's expertise for a condition
ConditionClose
  • Elite
  • Renal Cell Carcinoma (RCC)
    Dr. Hurwitz is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Hurwitz is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Hurwitz is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Hurwitz is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Prostate Cancer
    Dr. Hurwitz is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Familial Wilms Tumor 2
    Dr. Hurwitz is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Prostate Cancer
    Dr. Hurwitz is
    Distinguished
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
View All 8 Distinguished Conditions
  • Advanced
  • Bladder Cancer
    Dr. Hurwitz is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Choriocarcinoma
    Dr. Hurwitz is
    Advanced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Melanoma
    Dr. Hurwitz is
    Advanced
    . Learn about Melanoma.
    See more Melanoma experts
  • Muscle Invasive Bladder Cancer
    Dr. Hurwitz is
    Advanced
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Pseudomyxoma Peritonei
    Dr. Hurwitz is
    Advanced
    . Learn about Pseudomyxoma Peritonei.
    See more Pseudomyxoma Peritonei experts
  • Teratoma of the Mediastinum
    Dr. Hurwitz is
    Advanced
    . Learn about Teratoma of the Mediastinum.
    See more Teratoma of the Mediastinum experts
View All 8 Advanced Conditions
  • Experienced
  • Brain Tumor
    Dr. Hurwitz is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Desmoid Tumor
    Dr. Hurwitz is
    Experienced
    . Learn about Desmoid Tumor.
    See more Desmoid Tumor experts
  • Hypothalamic Hamartomas
    Dr. Hurwitz is
    Experienced
    . Learn about Hypothalamic Hamartomas.
    See more Hypothalamic Hamartomas experts
  • Lung Cancer
    Dr. Hurwitz is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Lymphofollicular Hyperplasia
    Dr. Hurwitz is
    Experienced
    . Learn about Lymphofollicular Hyperplasia.
    See more Lymphofollicular Hyperplasia experts
  • Merkel Cell Carcinoma
    Dr. Hurwitz is
    Experienced
    . Learn about Merkel Cell Carcinoma.
    See more Merkel Cell Carcinoma experts
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved